New, AI-based therapies require a flexible and safe legal framework in order to reach patients quickly and safely. In a new paper, published in npj Precision Oncology, researchers from Dresden, Leipzig, Marburg and Paris provide an overview of possible AI-based applications for personalized cancer medicine and the associated regulatory challenges. They emphasize that the current rigid and slow approval requirements impede technological progress and argue for an adaptation of the existing regulations.
You may also be interested in:
Babies who are breastfed, or partially breastfed, for more than six months are less likely to be given sugar-sweetened drinks and sweet or salty snacks [...]
Increased numbers of preterm births, higher incidence of respiratory disease and death, and more children in hospitals are some of the stark health outcomes the [...]
After a one-year interdisciplinary therapy program that included clinical, nutritional, psychological and exercise counseling, a group of 22 obese adolescents not only lost weight but [...]